Market Closed -
Nasdaq
21:00:00 21/06/2024 BST
|
5-day change
|
1st Jan Change
|
51.55
USD
|
+1.36%
|
|
+4.14%
|
+39.48%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,591
|
5,765
|
5,659
|
7,694
|
4,882
|
6,561
|
-
|
-
|
Enterprise Value (EV)
1 |
2,874
|
6,014
|
5,794
|
8,837
|
6,046
|
7,763
|
6,941
|
6,664
|
P/E ratio
|
-35.5
x
|
46.9
x
|
14.7
x
|
39.5
x
|
17.6
x
|
16
x
|
12.4
x
|
9.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.2
x
|
21.5
x
|
12.8
x
|
11.7
x
|
5.89
x
|
6.65
x
|
5.68
x
|
4.71
x
|
EV / Revenue
|
14.7
x
|
22.5
x
|
13.1
x
|
13.4
x
|
7.29
x
|
7.86
x
|
6.01
x
|
4.78
x
|
EV / EBITDA
|
-45.2
x
|
40.8
x
|
20.8
x
|
28.1
x
|
14.2
x
|
13.7
x
|
9.43
x
|
7.37
x
|
EV / FCF
|
-32.1
x
|
114
x
|
19.4
x
|
37.6
x
|
-
|
14
x
|
10.2
x
|
-
|
FCF Yield
|
-3.11%
|
0.88%
|
5.14%
|
2.66%
|
-
|
7.12%
|
9.77%
|
-
|
Price to Book
|
26.4
x
|
38.2
x
|
28.1
x
|
45.3
x
|
-
|
20.8
x
|
6.07
x
|
4.3
x
|
Nbr of stocks (in thousands)
|
146,142
|
134,972
|
140,725
|
135,213
|
132,098
|
127,274
|
-
|
-
|
Reference price
2 |
17.73
|
42.71
|
40.21
|
56.90
|
36.96
|
51.55
|
51.55
|
51.55
|
Announcement Date
|
24/02/20
|
23/02/21
|
22/02/22
|
21/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
196
|
267.6
|
443.3
|
660.1
|
829.3
|
987
|
1,154
|
1,393
|
EBITDA
1 |
-63.54
|
147.5
|
278.9
|
315
|
426.2
|
567.7
|
735.6
|
904.6
|
EBIT
1 |
-67.61
|
144.3
|
275.9
|
267.5
|
337.6
|
503
|
647.4
|
874.9
|
Operating Margin
|
-34.5%
|
53.91%
|
62.24%
|
40.53%
|
40.71%
|
50.96%
|
56.08%
|
62.81%
|
Earnings before Tax (EBT)
1 |
-72.25
|
129.3
|
248.5
|
248.9
|
348.3
|
500.6
|
654.6
|
844.5
|
Net income
1 |
-72.24
|
129.1
|
402.7
|
202.1
|
281.6
|
400.6
|
517.3
|
664.2
|
Net margin
|
-36.86%
|
48.24%
|
90.84%
|
30.62%
|
33.96%
|
40.59%
|
44.81%
|
47.68%
|
EPS
2 |
-0.5000
|
0.9100
|
2.740
|
1.440
|
2.100
|
3.221
|
4.147
|
5.678
|
Free Cash Flow
1 |
-89.46
|
52.95
|
298
|
235.3
|
-
|
553
|
678
|
-
|
FCF margin
|
-45.65%
|
19.79%
|
67.22%
|
35.65%
|
-
|
56.03%
|
58.73%
|
-
|
FCF Conversion (EBITDA)
|
-
|
35.89%
|
106.84%
|
74.7%
|
-
|
97.41%
|
92.16%
|
-
|
FCF Conversion (Net income)
|
-
|
41.02%
|
73.99%
|
116.41%
|
-
|
138.05%
|
131.07%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/02/20
|
23/02/21
|
22/02/22
|
21/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
102
|
117.3
|
152.4
|
209
|
181.5
|
162.1
|
221
|
216
|
230
|
195.9
|
209.1
|
272.6
|
310.1
|
260.6
|
270.7
|
EBITDA
1 |
57.31
|
81.19
|
40.84
|
85.3
|
79.45
|
74.54
|
115.1
|
114.9
|
121.7
|
115.7
|
113.8
|
167.1
|
180.3
|
159.4
|
165.8
|
EBIT
1 |
56.53
|
75.67
|
34.06
|
83.29
|
74.51
|
53.8
|
94.46
|
88.28
|
101
|
95.54
|
93.38
|
147.8
|
166.3
|
151.3
|
159.9
|
Operating Margin
|
55.42%
|
64.52%
|
22.35%
|
39.86%
|
41.05%
|
33.18%
|
42.73%
|
40.86%
|
43.92%
|
48.78%
|
44.65%
|
54.22%
|
53.63%
|
58.05%
|
59.05%
|
Earnings before Tax (EBT)
1 |
54.81
|
74.41
|
30.01
|
73.71
|
70.79
|
52.24
|
93.16
|
101.8
|
101.2
|
96.03
|
93.08
|
145.1
|
166.6
|
150.6
|
162.2
|
Net income
1 |
66.77
|
60.11
|
22.68
|
61.63
|
57.7
|
39.62
|
74.75
|
81.84
|
85.39
|
76.82
|
75.25
|
116
|
132.5
|
120.6
|
130
|
Net margin
|
65.46%
|
51.25%
|
14.89%
|
29.49%
|
31.79%
|
24.43%
|
33.82%
|
37.88%
|
37.12%
|
39.22%
|
35.98%
|
42.54%
|
42.72%
|
46.29%
|
48.02%
|
EPS
2 |
0.4600
|
0.4300
|
0.1600
|
0.4400
|
0.4200
|
0.2900
|
0.5700
|
0.6100
|
0.6500
|
0.6000
|
0.6100
|
0.9312
|
1.058
|
1.007
|
1.040
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/22
|
10/05/22
|
09/08/22
|
08/11/22
|
21/02/23
|
09/05/23
|
08/08/23
|
06/11/23
|
20/02/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
282
|
250
|
136
|
1,143
|
1,163
|
1,202
|
380
|
103
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-4.444
x
|
1.691
x
|
0.4867
x
|
3.63
x
|
2.729
x
|
2.117
x
|
0.5162
x
|
0.114
x
|
Free Cash Flow
1 |
-89.5
|
53
|
298
|
235
|
-
|
553
|
678
|
-
|
ROE (net income / shareholders' equity)
|
-42.4%
|
106%
|
169%
|
110%
|
293%
|
271%
|
86.7%
|
76.6%
|
ROA (Net income/ Total Assets)
|
-14.4%
|
22.5%
|
34.9%
|
13.7%
|
20.8%
|
29.6%
|
31.4%
|
30.8%
|
Assets
1 |
503.1
|
572.9
|
1,153
|
1,473
|
1,354
|
1,352
|
1,649
|
2,154
|
Book Value Per Share
2 |
0.6700
|
1.120
|
1.430
|
1.260
|
-
|
2.470
|
8.500
|
12.00
|
Cash Flow per Share
2 |
-
|
0.3900
|
2.040
|
1.710
|
-
|
3.620
|
-
|
-
|
Capex
1 |
4.04
|
2.5
|
1.46
|
4.81
|
-
|
5
|
2
|
-
|
Capex / Sales
|
2.06%
|
0.94%
|
0.33%
|
0.73%
|
-
|
0.51%
|
0.17%
|
-
|
Announcement Date
|
24/02/20
|
23/02/21
|
22/02/22
|
21/02/23
|
20/02/24
|
-
|
-
|
-
|
Last Close Price
51.55
USD Average target price
57.11
USD Spread / Average Target +10.79% Consensus |
1st Jan change
|
Capi.
|
---|
| +39.48% | 6.56B | | +15.19% | 121B | | +19.91% | 114B | | +8.24% | 23.61B | | -19.80% | 20.43B | | -16.19% | 16.55B | | -13.45% | 16.45B | | -44.35% | 15.59B | | +66.67% | 15.19B | | +2.13% | 13.54B |
Bio Therapeutic Drugs
|